Brought to you by 
NeoPharm licenses immunotoxin from National Cancer Institute
25 Nov 2002
Executive Summary
NeoPharm Inc. has licensed exclusive worldwide rights to the National Cancer Institute's SS(dsFv)-PE38, a single chain monoclonal antibody linked to pseudomonas exotoxin PE-38, to treat ovarian cancer and mesotheliomas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeoPharm licenses immunotoxin from National Cancer Institute
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice